4-Hydroxybutenolide impairs cell migration, and invasion of human oral cancer SCC-4 cells via the inhibition of NF-κB and MAPK signaling pathways.
Identifieur interne : 000166 ( Main/Exploration ); précédent : 000165; suivant : 0001674-Hydroxybutenolide impairs cell migration, and invasion of human oral cancer SCC-4 cells via the inhibition of NF-κB and MAPK signaling pathways.
Auteurs : Fu-Shun Yu [République populaire de Chine] ; Meng-Liang Lin [République populaire de Chine] ; Shu-Chun Hsu [République populaire de Chine] ; Chien-Chih Yu [République populaire de Chine] ; Yi-Ping Huang [République populaire de Chine] ; Yueh-Hsiung Kuo [République populaire de Chine] ; Jing-Gung Chung [République populaire de Chine]Source :
- International journal of oncology [ 1791-2423 ] ; 2016.
Descripteurs français
- KwdFr :
- 4-Butyrolactone (pharmacologie), Carcinome épidermoïde (anatomopathologie), Carcinome épidermoïde (métabolisme), Carcinome épidermoïde (traitement médicamenteux), Carcinome épidermoïde de la tête et du cou (MeSH), Facteur de transcription NF-kappa B (antagonistes et inhibiteurs), Facteur de transcription NF-kappa B (métabolisme), Humains (MeSH), Inhibiteurs de métalloprotéinases matricielles (pharmacologie), Invasion tumorale (MeSH), Lignée cellulaire tumorale (MeSH), Matrix metalloproteinase 2 (métabolisme), Matrix metalloproteinase 9 (métabolisme), Mouvement cellulaire (effets des médicaments et des substances chimiques), Système de signalisation des MAP kinases (effets des médicaments et des substances chimiques), Tumeurs de la bouche (anatomopathologie), Tumeurs de la bouche (métabolisme), Tumeurs de la bouche (traitement médicamenteux), Tumeurs de la tête et du cou (anatomopathologie), Tumeurs de la tête et du cou (métabolisme), Tumeurs de la tête et du cou (traitement médicamenteux).
- MESH :
- anatomopathologie : Carcinome épidermoïde, Tumeurs de la bouche, Tumeurs de la tête et du cou.
- antagonistes et inhibiteurs : Facteur de transcription NF-kappa B.
- effets des médicaments et des substances chimiques : Mouvement cellulaire, Système de signalisation des MAP kinases.
- métabolisme : Carcinome épidermoïde, Facteur de transcription NF-kappa B, Matrix metalloproteinase 2, Matrix metalloproteinase 9, Tumeurs de la bouche, Tumeurs de la tête et du cou.
- pharmacologie : 4-Butyrolactone, Inhibiteurs de métalloprotéinases matricielles.
- traitement médicamenteux : Carcinome épidermoïde, Tumeurs de la bouche, Tumeurs de la tête et du cou.
- Carcinome épidermoïde de la tête et du cou, Humains, Invasion tumorale, Lignée cellulaire tumorale.
English descriptors
- KwdEn :
- 4-Butyrolactone (pharmacology), Carcinoma, Squamous Cell (drug therapy), Carcinoma, Squamous Cell (metabolism), Carcinoma, Squamous Cell (pathology), Cell Line, Tumor (MeSH), Cell Movement (drug effects), Head and Neck Neoplasms (drug therapy), Head and Neck Neoplasms (metabolism), Head and Neck Neoplasms (pathology), Humans (MeSH), MAP Kinase Signaling System (drug effects), Matrix Metalloproteinase 2 (metabolism), Matrix Metalloproteinase 9 (metabolism), Matrix Metalloproteinase Inhibitors (pharmacology), Mouth Neoplasms (drug therapy), Mouth Neoplasms (metabolism), Mouth Neoplasms (pathology), NF-kappa B (antagonists & inhibitors), NF-kappa B (metabolism), Neoplasm Invasiveness (MeSH), Squamous Cell Carcinoma of Head and Neck (MeSH).
- MESH :
- chemical , antagonists & inhibitors : NF-kappa B.
- chemical , metabolism : Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, NF-kappa B.
- chemical , pharmacology : 4-Butyrolactone, Matrix Metalloproteinase Inhibitors.
- drug effects : Cell Movement, MAP Kinase Signaling System.
- drug therapy : Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms.
- metabolism : Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms.
- pathology : Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms.
- Cell Line, Tumor, Humans, Neoplasm Invasiveness, Squamous Cell Carcinoma of Head and Neck.
Abstract
4-Hydroxybutenolide (K87), a synthetic compound from furfuryl alcohol via photooxidation, was used to investigate whether it can inhibit mobility, migration and invasion of SCC-4 human oral cancer cells in vitro. Cell viability was measured by flow cytometric assay, the enzymatic activities of MMP-2/9 were assayed by gelatin zymography analysis, the protein levels were assayed by western blotting, confocal laser microscopy and EMSA assay, and the gene expression of MMP-2/-7, FAK and ROCK1 mRNA were assayed by PCR. K87 decreased the percentage of viable cells in dose-dependent manner. K87 suppressed cell mobility, migration and invasion of SCC-4 cells dose-dependently. K87 inhibited the enzymatic activities of MMP-2/9 of SCC-4 cells. Western blot analysis revealed that K87 decreased the protein levels in NF-κBp65, COX-2, ROCK1 and Rho A, MMP-1, -2,- 7, -9, VEGF, GRB2, SOS1, PI3K, PKC, PERK, p-PERK, FAK, MEKK3, MKK7, ERK1/2, JNK1/2, p-p38, p38, p-c-Jun, AKT, TIMP2, but increased the protein levels of iNOS, Ras, IRE-1α, p-c-JNK, p-AKT(308), p-AKT(473) and TIMP1. Results from PCR indicated that K87 inhibited the gene expression of MMP-2/-7, FAK and ROCK1 mRNA. Furthermore, confocal laser microscopy was used to confirm that K87 inhibited the translocation of RHOA and ROCK1 in SCC-4 cells. EMSA assay also show that K87 suppressed the nuclear activation of NF-κB and these effects are time-dependent. Western blotting assay indicated that expression of NF-κBp105, NF-κBp50 and NF-κBp65 proteins were decreased and these effects are time-dependent. Based on these observations, we suggest that K87 may be used as a potential agent for anticancer metastasis of human oral cancer in the future.
DOI: 10.3892/ijo.2016.3537
PubMed: 27221634
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">4-Hydroxybutenolide impairs cell migration, and invasion of human oral cancer SCC-4 cells via the inhibition of NF-κB and MAPK signaling pathways.</title><author><name sortKey="Yu, Fu Shun" sort="Yu, Fu Shun" uniqKey="Yu F" first="Fu-Shun" last="Yu">Fu-Shun Yu</name><affiliation wicri:level="1"><nlm:affiliation>School of Dentist, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Dentist, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Lin, Meng Liang" sort="Lin, Meng Liang" uniqKey="Lin M" first="Meng-Liang" last="Lin">Meng-Liang Lin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Hsu, Shu Chun" sort="Hsu, Shu Chun" uniqKey="Hsu S" first="Shu-Chun" last="Hsu">Shu-Chun Hsu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Yu, Chien Chih" sort="Yu, Chien Chih" uniqKey="Yu C" first="Chien-Chih" last="Yu">Chien-Chih Yu</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Pharmacy, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Yi Ping" sort="Huang, Yi Ping" uniqKey="Huang Y" first="Yi-Ping" last="Huang">Yi-Ping Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Physiology, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Kuo, Yueh Hsiung" sort="Kuo, Yueh Hsiung" uniqKey="Kuo Y" first="Yueh-Hsiung" last="Kuo">Yueh-Hsiung Kuo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Chung, Jing Gung" sort="Chung, Jing Gung" uniqKey="Chung J" first="Jing-Gung" last="Chung">Jing-Gung Chung</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27221634</idno><idno type="pmid">27221634</idno><idno type="doi">10.3892/ijo.2016.3537</idno><idno type="wicri:Area/Main/Corpus">000144</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000144</idno><idno type="wicri:Area/Main/Curation">000144</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000144</idno><idno type="wicri:Area/Main/Exploration">000144</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">4-Hydroxybutenolide impairs cell migration, and invasion of human oral cancer SCC-4 cells via the inhibition of NF-κB and MAPK signaling pathways.</title><author><name sortKey="Yu, Fu Shun" sort="Yu, Fu Shun" uniqKey="Yu F" first="Fu-Shun" last="Yu">Fu-Shun Yu</name><affiliation wicri:level="1"><nlm:affiliation>School of Dentist, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Dentist, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Lin, Meng Liang" sort="Lin, Meng Liang" uniqKey="Lin M" first="Meng-Liang" last="Lin">Meng-Liang Lin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Hsu, Shu Chun" sort="Hsu, Shu Chun" uniqKey="Hsu S" first="Shu-Chun" last="Hsu">Shu-Chun Hsu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Yu, Chien Chih" sort="Yu, Chien Chih" uniqKey="Yu C" first="Chien-Chih" last="Yu">Chien-Chih Yu</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Pharmacy, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Yi Ping" sort="Huang, Yi Ping" uniqKey="Huang Y" first="Yi-Ping" last="Huang">Yi-Ping Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Physiology, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Kuo, Yueh Hsiung" sort="Kuo, Yueh Hsiung" uniqKey="Kuo Y" first="Yueh-Hsiung" last="Kuo">Yueh-Hsiung Kuo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Chung, Jing Gung" sort="Chung, Jing Gung" uniqKey="Chung J" first="Jing-Gung" last="Chung">Jing-Gung Chung</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author></analytic><series><title level="j">International journal of oncology</title><idno type="eISSN">1791-2423</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>4-Butyrolactone (pharmacology)</term><term>Carcinoma, Squamous Cell (drug therapy)</term><term>Carcinoma, Squamous Cell (metabolism)</term><term>Carcinoma, Squamous Cell (pathology)</term><term>Cell Line, Tumor (MeSH)</term><term>Cell Movement (drug effects)</term><term>Head and Neck Neoplasms (drug therapy)</term><term>Head and Neck Neoplasms (metabolism)</term><term>Head and Neck Neoplasms (pathology)</term><term>Humans (MeSH)</term><term>MAP Kinase Signaling System (drug effects)</term><term>Matrix Metalloproteinase 2 (metabolism)</term><term>Matrix Metalloproteinase 9 (metabolism)</term><term>Matrix Metalloproteinase Inhibitors (pharmacology)</term><term>Mouth Neoplasms (drug therapy)</term><term>Mouth Neoplasms (metabolism)</term><term>Mouth Neoplasms (pathology)</term><term>NF-kappa B (antagonists & inhibitors)</term><term>NF-kappa B (metabolism)</term><term>Neoplasm Invasiveness (MeSH)</term><term>Squamous Cell Carcinoma of Head and Neck (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>4-Butyrolactone (pharmacologie)</term><term>Carcinome épidermoïde (anatomopathologie)</term><term>Carcinome épidermoïde (métabolisme)</term><term>Carcinome épidermoïde (traitement médicamenteux)</term><term>Carcinome épidermoïde de la tête et du cou (MeSH)</term><term>Facteur de transcription NF-kappa B (antagonistes et inhibiteurs)</term><term>Facteur de transcription NF-kappa B (métabolisme)</term><term>Humains (MeSH)</term><term>Inhibiteurs de métalloprotéinases matricielles (pharmacologie)</term><term>Invasion tumorale (MeSH)</term><term>Lignée cellulaire tumorale (MeSH)</term><term>Matrix metalloproteinase 2 (métabolisme)</term><term>Matrix metalloproteinase 9 (métabolisme)</term><term>Mouvement cellulaire (effets des médicaments et des substances chimiques)</term><term>Système de signalisation des MAP kinases (effets des médicaments et des substances chimiques)</term><term>Tumeurs de la bouche (anatomopathologie)</term><term>Tumeurs de la bouche (métabolisme)</term><term>Tumeurs de la bouche (traitement médicamenteux)</term><term>Tumeurs de la tête et du cou (anatomopathologie)</term><term>Tumeurs de la tête et du cou (métabolisme)</term><term>Tumeurs de la tête et du cou (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>NF-kappa B</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Matrix Metalloproteinase 2</term><term>Matrix Metalloproteinase 9</term><term>NF-kappa B</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>4-Butyrolactone</term><term>Matrix Metalloproteinase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Tumeurs de la bouche</term><term>Tumeurs de la tête et du cou</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de transcription NF-kappa B</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Movement</term><term>MAP Kinase Signaling System</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Head and Neck Neoplasms</term><term>Mouth Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Mouvement cellulaire</term><term>Système de signalisation des MAP kinases</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Head and Neck Neoplasms</term><term>Mouth Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Facteur de transcription NF-kappa B</term><term>Matrix metalloproteinase 2</term><term>Matrix metalloproteinase 9</term><term>Tumeurs de la bouche</term><term>Tumeurs de la tête et du cou</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Head and Neck Neoplasms</term><term>Mouth Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>4-Butyrolactone</term><term>Inhibiteurs de métalloprotéinases matricielles</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Tumeurs de la bouche</term><term>Tumeurs de la tête et du cou</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line, Tumor</term><term>Humans</term><term>Neoplasm Invasiveness</term><term>Squamous Cell Carcinoma of Head and Neck</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Carcinome épidermoïde de la tête et du cou</term><term>Humains</term><term>Invasion tumorale</term><term>Lignée cellulaire tumorale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">4-Hydroxybutenolide (K87), a synthetic compound from furfuryl alcohol via photooxidation, was used to investigate whether it can inhibit mobility, migration and invasion of SCC-4 human oral cancer cells in vitro. Cell viability was measured by flow cytometric assay, the enzymatic activities of MMP-2/9 were assayed by gelatin zymography analysis, the protein levels were assayed by western blotting, confocal laser microscopy and EMSA assay, and the gene expression of MMP-2/-7, FAK and ROCK1 mRNA were assayed by PCR. K87 decreased the percentage of viable cells in dose-dependent manner. K87 suppressed cell mobility, migration and invasion of SCC-4 cells dose-dependently. K87 inhibited the enzymatic activities of MMP-2/9 of SCC-4 cells. Western blot analysis revealed that K87 decreased the protein levels in NF-κBp65, COX-2, ROCK1 and Rho A, MMP-1, -2,- 7, -9, VEGF, GRB2, SOS1, PI3K, PKC, PERK, p-PERK, FAK, MEKK3, MKK7, ERK1/2, JNK1/2, p-p38, p38, p-c-Jun, AKT, TIMP2, but increased the protein levels of iNOS, Ras, IRE-1α, p-c-JNK, p-AKT(308), p-AKT(473) and TIMP1. Results from PCR indicated that K87 inhibited the gene expression of MMP-2/-7, FAK and ROCK1 mRNA. Furthermore, confocal laser microscopy was used to confirm that K87 inhibited the translocation of RHOA and ROCK1 in SCC-4 cells. EMSA assay also show that K87 suppressed the nuclear activation of NF-κB and these effects are time-dependent. Western blotting assay indicated that expression of NF-κBp105, NF-κBp50 and NF-κBp65 proteins were decreased and these effects are time-dependent. Based on these observations, we suggest that K87 may be used as a potential agent for anticancer metastasis of human oral cancer in the future. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27221634</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-2423</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of oncology</Title><ISOAbbreviation>Int J Oncol</ISOAbbreviation></Journal><ArticleTitle>4-Hydroxybutenolide impairs cell migration, and invasion of human oral cancer SCC-4 cells via the inhibition of NF-κB and MAPK signaling pathways.</ArticleTitle><Pagination><MedlinePgn>579-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3892/ijo.2016.3537</ELocationID><Abstract><AbstractText>4-Hydroxybutenolide (K87), a synthetic compound from furfuryl alcohol via photooxidation, was used to investigate whether it can inhibit mobility, migration and invasion of SCC-4 human oral cancer cells in vitro. Cell viability was measured by flow cytometric assay, the enzymatic activities of MMP-2/9 were assayed by gelatin zymography analysis, the protein levels were assayed by western blotting, confocal laser microscopy and EMSA assay, and the gene expression of MMP-2/-7, FAK and ROCK1 mRNA were assayed by PCR. K87 decreased the percentage of viable cells in dose-dependent manner. K87 suppressed cell mobility, migration and invasion of SCC-4 cells dose-dependently. K87 inhibited the enzymatic activities of MMP-2/9 of SCC-4 cells. Western blot analysis revealed that K87 decreased the protein levels in NF-κBp65, COX-2, ROCK1 and Rho A, MMP-1, -2,- 7, -9, VEGF, GRB2, SOS1, PI3K, PKC, PERK, p-PERK, FAK, MEKK3, MKK7, ERK1/2, JNK1/2, p-p38, p38, p-c-Jun, AKT, TIMP2, but increased the protein levels of iNOS, Ras, IRE-1α, p-c-JNK, p-AKT(308), p-AKT(473) and TIMP1. Results from PCR indicated that K87 inhibited the gene expression of MMP-2/-7, FAK and ROCK1 mRNA. Furthermore, confocal laser microscopy was used to confirm that K87 inhibited the translocation of RHOA and ROCK1 in SCC-4 cells. EMSA assay also show that K87 suppressed the nuclear activation of NF-κB and these effects are time-dependent. Western blotting assay indicated that expression of NF-κBp105, NF-κBp50 and NF-κBp65 proteins were decreased and these effects are time-dependent. Based on these observations, we suggest that K87 may be used as a potential agent for anticancer metastasis of human oral cancer in the future. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Fu-Shun</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>School of Dentist, China Medical University, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Meng-Liang</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Shu-Chun</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chien-Chih</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>School of Pharmacy, China Medical University, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yi-Ping</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Department of Physiology, China Medical University, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Yueh-Hsiung</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jing-Gung</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Int J Oncol</MedlineTA><NlmUniqueID>9306042</NlmUniqueID><ISSNLinking>1019-6439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061965">Matrix Metalloproteinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.24</RegistryNumber><NameOfSubstance UI="C522361">MMP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.24</RegistryNumber><NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="C579270">MMP9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>OL659KIY4X</RegistryNumber><NameOfSubstance UI="D015107">4-Butyrolactone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015107" MajorTopicYN="N">4-Butyrolactone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061965" MajorTopicYN="N">Matrix Metalloproteinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009062" MajorTopicYN="N">Mouth Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="N">Squamous Cell Carcinoma of Head and Neck</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27221634</ArticleId><ArticleId IdType="doi">10.3892/ijo.2016.3537</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Yu, Fu Shun" sort="Yu, Fu Shun" uniqKey="Yu F" first="Fu-Shun" last="Yu">Fu-Shun Yu</name></noRegion><name sortKey="Chung, Jing Gung" sort="Chung, Jing Gung" uniqKey="Chung J" first="Jing-Gung" last="Chung">Jing-Gung Chung</name><name sortKey="Hsu, Shu Chun" sort="Hsu, Shu Chun" uniqKey="Hsu S" first="Shu-Chun" last="Hsu">Shu-Chun Hsu</name><name sortKey="Huang, Yi Ping" sort="Huang, Yi Ping" uniqKey="Huang Y" first="Yi-Ping" last="Huang">Yi-Ping Huang</name><name sortKey="Kuo, Yueh Hsiung" sort="Kuo, Yueh Hsiung" uniqKey="Kuo Y" first="Yueh-Hsiung" last="Kuo">Yueh-Hsiung Kuo</name><name sortKey="Lin, Meng Liang" sort="Lin, Meng Liang" uniqKey="Lin M" first="Meng-Liang" last="Lin">Meng-Liang Lin</name><name sortKey="Yu, Chien Chih" sort="Yu, Chien Chih" uniqKey="Yu C" first="Chien-Chih" last="Yu">Chien-Chih Yu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SuicidDentistV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000166 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000166 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SuicidDentistV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27221634
|texte= 4-Hydroxybutenolide impairs cell migration, and invasion of human oral cancer SCC-4 cells via the inhibition of NF-κB and MAPK signaling pathways.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27221634" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SuicidDentistV1
| This area was generated with Dilib version V0.6.39. |  |